These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 15863158)
1. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Spillman MA; Schildkraut JM; Halabi S; Moorman P; Calingaert B; Bentley RC; Marks JR; Murphy S; Berchuck A Gynecol Oncol; 2005 May; 97(2):543-9. PubMed ID: 15863158 [TBL] [Abstract][Full Text] [Related]
2. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. Kaklamani VG; Hou N; Bian Y; Reich J; Offit K; Michel LS; Rubinstein WS; Rademaker A; Pasche B J Clin Oncol; 2003 Sep; 21(17):3236-43. PubMed ID: 12947057 [TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511 [TBL] [Abstract][Full Text] [Related]
4. TbetaR-I(6A) is a candidate tumor susceptibility allele. Pasche B; Kolachana P; Nafa K; Satagopan J; Chen YG; Lo RS; Brener D; Yang D; Kirstein L; Oddoux C; Ostrer H; Vineis P; Varesco L; Jhanwar S; Luzzatto L; Massagué J; Offit K Cancer Res; 1999 Nov; 59(22):5678-82. PubMed ID: 10582683 [TBL] [Abstract][Full Text] [Related]
5. Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Kaklamani VG; Baddi L; Liu J; Rosman D; Phukan S; Bradley C; Hegarty C; McDaniel B; Rademaker A; Oddoux C; Ostrer H; Michel LS; Huang H; Chen Y; Ahsan H; Offit K; Pasche B Cancer Res; 2005 Apr; 65(8):3454-61. PubMed ID: 15833881 [TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Berchuck A; Schildkraut JM; Wenham RM; Calingaert B; Ali S; Henriott A; Halabi S; Rodriguez GC; Gertig D; Purdie DM; Kelemen L; Spurdle AB; Marks J; Chenevix-Trench G Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2141-7. PubMed ID: 15598772 [TBL] [Abstract][Full Text] [Related]
7. Lack of an association between the TGFBR1*6A variant and colorectal cancer risk. Skoglund J; Song B; Dalén J; Dedorson S; Edler D; Hjern F; Holm J; Lenander C; Lindforss U; Lundqvist N; Olivecrona H; Olsson L; Påhlman L; Rutegård J; Smedh K; Törnqvist A; Houlston RS; Lindblom A Clin Cancer Res; 2007 Jun; 13(12):3748-52. PubMed ID: 17575241 [TBL] [Abstract][Full Text] [Related]
8. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Lurie G; Wilkens LR; Thompson PJ; McDuffie KE; Carney ME; Terada KY; Goodman MT Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2566-71. PubMed ID: 18086759 [TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Li Y; Jin X; Kang S; Wang Y; Du H; Zhang J; Guo W; Wang N; Fang S Gynecol Oncol; 2006 Apr; 101(1):92-6. PubMed ID: 16278009 [TBL] [Abstract][Full Text] [Related]
10. Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer. Leite DB; Junqueira MG; de Carvalho CV; Massad-Costa AM; Gonçalves WJ; Nicolau SM; Lopes LA; Baracat EC; da Silva ID Steroids; 2008 Jul; 73(6):676-80. PubMed ID: 18384825 [TBL] [Abstract][Full Text] [Related]
11. No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. Lancaster JM; Wenham RM; Halabi S; Calingaert B; Marks JR; Moorman PG; Bentley RC; Berchuck A; Schildkraut JM Cancer Epidemiol Biomarkers Prev; 2003 Mar; 12(3):226-7. PubMed ID: 12646513 [No Abstract] [Full Text] [Related]
12. The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer. Colleran G; McInerney N; Rowan A; Barclay E; Jones AM; Curran C; Miller N; Kerin M; Tomlinson I; Sawyer E Breast Cancer Res Treat; 2010 Jan; 119(2):437-42. PubMed ID: 19390964 [TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor beta receptor 1 polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer. Baxter SW; Choong DY; Eccles DM; Campbell IG Cancer Epidemiol Biomarkers Prev; 2002 Feb; 11(2):211-4. PubMed ID: 11867510 [No Abstract] [Full Text] [Related]
14. PGR +331 A/G and increased risk of epithelial ovarian cancer. Risch HA; Bale AE; Beck PA; Zheng W Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1738-41. PubMed ID: 16985038 [TBL] [Abstract][Full Text] [Related]
15. The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer. Fung WL; Risch H; McLaughlin J; Rosen B; Cole D; Vesprini D; Narod SA Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):678-80. PubMed ID: 12869412 [TBL] [Abstract][Full Text] [Related]
16. Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Pasche B; Luo Y; Rao PH; Nimer SD; Dmitrovsky E; Caron P; Luzzatto L; Offit K; Cordon-Cardo C; Renault B; Satagopan JM; Murty VV; Massagué J Cancer Res; 1998 Jul; 58(13):2727-32. PubMed ID: 9661882 [TBL] [Abstract][Full Text] [Related]
18. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women. Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674 [TBL] [Abstract][Full Text] [Related]
19. An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers. Konac E; Onen HI; Metindir J; Alp E; Biri AA; Ekmekci A Cancer Detect Prev; 2007; 31(2):102-9. PubMed ID: 17418979 [TBL] [Abstract][Full Text] [Related]
20. Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer. Romano A; Lindsey PJ; Fischer DC; Delvoux B; Paulussen AD; Janssen RG; Kieback DG Gynecol Oncol; 2006 May; 101(2):287-95. PubMed ID: 16360811 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]